-
公开(公告)号:US07589193B2
公开(公告)日:2009-09-15
申请号:US11233617
申请日:2005-09-23
申请人: William Washburn , Wei Meng
发明人: William Washburn , Wei Meng
IPC分类号: C07H7/04
摘要: A compound of the formula I A method is also provided for treating diabetes and related diseases employing the above compound alone or in combination with another therapeutic agent.
摘要翻译: 还提供了式IA方法的化合物,用于单独使用上述化合物或与另一种治疗剂组合治疗糖尿病和相关疾病。
-
公开(公告)号:US5705489A
公开(公告)日:1998-01-06
申请号:US690449
申请日:1996-08-05
IPC分类号: C07H7/033 , A61K20060101 , A61K31/70 , A61K31/7012 , A61K47/48 , A61P7/02 , A61P43/00 , C07H20060101 , C07H3/06 , C07H7/04 , C07H11/00 , C07H13/00 , C07H15/04 , C07H15/08 , C07H15/18 , C07H15/22 , C07H15/26 , C07K9/00 , C08B37/00 , C08B37/10 , C07H15/00
摘要: The invention relates to a tuneable bisconjugate comprising two saccharides and a spacer, each saccharide being the same or different and comprising two to six monosaccharide units, at least one unit being uronic acid, characterized in that at least one of the saccharides per se has anti-thrombotic activity, and that the spacer connects at least one saccharide to the other through its non-reducing end, the chain length of the spacer being 20-120 atoms.
摘要翻译: 本发明涉及包含两种糖类和间隔物的可调式双缀合物,每种糖相同或不同,并且包含两至六个单糖单元,至少一个单元是糖醛酸,其特征在于,至少一种糖本身具有抗 并且间隔物通过其非还原性末端将至少一个糖连接到另一个,间隔物的链长为20-120个原子。
-
公开(公告)号:US5424406A
公开(公告)日:1995-06-13
申请号:US149912
申请日:1993-11-10
IPC分类号: A61K31/70 , A61K31/7056 , C07H15/203 , C07H7/04 , C07H15/04
CPC分类号: A61K31/7034 , A61K31/70 , A61K31/7048 , A61K31/7056 , A61K31/706 , C07H15/203
摘要: A method for treatment of diabetes, which comprises administering to a patient with diabetes an effective amount of a dihydrochalcone derivative of the formula: ##STR1## wherein Ar is an aryl group, R.sup.1 is a hydrogen atom or an acyl group, R.sup.2 is a hydrogen atom, an acyl group or .alpha.-D-glucopyranosyl group, or R.sup.1 and R.sup.2 may combine together to form a substituted methylene group, R.sup.3 and R.sup.4 are each a hydrogen atom or an acyl group, OR.sup.5 is a protected or unprotected hydroxy group or a lower alkoxy group; or a pharmaceutically acceptable salt thereof.
摘要翻译: 一种治疗糖尿病的方法,其包括向糖尿病患者施用有效量的下式的二氢查耳酮衍生物:其中Ar为芳基,R 1为氢原子或酰基,R 2为氢 原子,酰基或α-D-吡喃葡萄糖基,或R 1和R 2可以结合在一起形成取代的亚甲基,R 3和R 4各自为氢原子或酰基,OR 5为被保护或未被保护的羟基或 低级烷氧基; 或其药学上可接受的盐。
-
公开(公告)号:US4552895A
公开(公告)日:1985-11-12
申请号:US475272
申请日:1983-03-14
IPC分类号: C07D307/93 , A61K31/70 , A61P35/00 , C07D493/04 , C07D493/08 , C07H7/04 , A61K31/365
CPC分类号: C07D493/04
摘要: The invention provides for certain compounds derived from ascorbic acid and their formulations which are useful in inhibiting angiogenesis in mammals.
摘要翻译: 本发明提供了一些衍生自抗坏血酸的化合物及其制剂,其可用于抑制哺乳动物的血管发生。
-
公开(公告)号:US20220324897A1
公开(公告)日:2022-10-13
申请号:US17596900
申请日:2020-07-03
发明人: Qinghua MAO , Tao YU , Yi LI , Chengde WU , Ting YAO
摘要: Crystal form A of a compound represented by formula (I) and an application thereof in preparing a drug for treating an SGLT1/SGLT2-related disease.
-
公开(公告)号:USRE49080E1
公开(公告)日:2022-05-24
申请号:US16793734
申请日:2020-02-18
申请人: Novartis AG
发明人: Gregory Raymond Bebernitz , Mark G. Bock , Dumbala Srinivas Reddy , Atul Kashinath Hajare , Vinod Vyavahare , Sandeep Bhausaheb Bhosale , Suresh Eknath Kurhade , Videsh Salunkhe , Nadim S. Shaikh , Debnath Bhuniya , P. Venkata Palle , Lili Feng , Jessica Liang
IPC分类号: A61K31/7052 , A61K31/7048 , A61K31/706 , C07D405/10 , C07D407/10 , C07D413/10 , C07H7/04
摘要: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
-
公开(公告)号:US11084842B2
公开(公告)日:2021-08-10
申请号:US16960488
申请日:2019-01-22
发明人: Zheng Gu , Wuyong Wu , Tong Qu , Panpan Kang , Zongyuan Zhang , Weiming Huang , Jianyu Liu , Yingjun Zhang
IPC分类号: C07H7/04 , C07H15/207
摘要: A glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases.
-
公开(公告)号:US11072625B2
公开(公告)日:2021-07-27
申请号:US16339646
申请日:2017-10-06
申请人: GLYCOMIMETICS, INC.
发明人: John L. Magnani , John M. Peterson , Myung-Gi Baek
摘要: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, highly potent multimeric E-selectin antagonist are desorbed and pharmaceutical compositions comprising at least one of the same.
-
79.
公开(公告)号:US20210205324A1
公开(公告)日:2021-07-08
申请号:US17073827
申请日:2020-10-19
IPC分类号: A61K31/5513 , A61K31/4515 , A61K31/551 , A61K31/7034 , A61K31/7048 , A61K45/06 , C07H7/04 , A61K31/351 , A61K31/381
摘要: The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an SGLT2 inhibitor.
-
公开(公告)号:US10570112B2
公开(公告)日:2020-02-25
申请号:US16045047
申请日:2018-07-25
申请人: FUJIFILM Corporation
发明人: Kouki Nakamura , Satoshi Shimamura , Junichi Imoto , Motomasa Takahashi , Katsuyuki Watanabe , Kenji Wada , Yuuta Fujino , Takuya Matsumoto , Makoto Takahashi , Hideki Okada , Takehiro Yamane , Takayuki Ito
IPC分类号: C07C47/277 , C07D333/32 , C07F7/18 , C07C67/29 , C07C68/06 , C07C69/28 , C07C69/618 , C07C69/76 , C07C69/92 , C07C69/96 , A61K31/7068 , C07C303/28 , C07C45/00 , C07B53/00 , C07C309/73 , C07C249/04 , C07C251/38 , C07H13/04 , C07H13/08 , C07H15/04 , C07H15/18 , C07H15/203 , C07H17/02 , C07H19/067 , C07H19/073 , C07H23/00 , C07H19/06 , C07C69/78 , C07H1/00 , C07H7/04 , C07C251/40 , C07C309/66
摘要: A compound represented by a formula [1D] as shown below (wherein R1A, R1B, R2A, R2B, R3A and R3B represent a hydrogen atom, an optionally substituted C1-6 alkyl group, and the like) is useful as an intermediate for producing a thionucleoside, and the production method of the present invention is useful as a method for producing a thionucleoside.
-
-
-
-
-
-
-
-
-